Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study
- PMID: 23199849
- DOI: 10.1016/S0140-6736(12)61426-3
Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study
Abstract
Background: Statins are commonly prescribed for management of dyslipidaemia and cardiovascular disease. Increased fitness is also associated with low mortality and is recommended as an essential part of promoting health. However, little information exists about the combined effects of fitness and statin treatment on all-cause mortality. We assessed the combined effects of statin treatment and fitness on all-cause mortality risk.
Methods: In this prospective cohort study, we included dyslipidaemic veterans from Veterans Affairs Medical Centers in Palo Alto, CA, and Washington DC, USA, who had had an exercise tolerance test between 1986, and 2011. We assigned participants to one of four fitness categories based on peak metabolic equivalents (MET) achieved during exercise test and eight categories based on fitness status and statin treatment. The primary endpoint was all-cause mortality adjusted for age, body-mass index, ethnic origin, sex, history of cardiovascular disease, cardiovascular drugs, and cardiovascular risk factors. We assessed mortality from Veteran's Affairs' records on Dec 31, 2011. We compared groups with Cox proportional hazard model.
Findings: We assessed 10,043 participants (mean age 58·8 years, SD 10·9 years). During a median follow-up of 10·0 years (IQR 6·0-14·2), 2318 patients died, with an average yearly mortality rate of 22 deaths per 1000 person-years. Mortality risk was 18·5% (935/5046) in people taking statins versus 27·7% (1386/4997) in those not taking statins (p<0·0001). In patients who took statins, mortality risk decreased as fitness increased; for highly fit individuals (>9 MET; n=694), the hazard ratio (HR) was 0·30 (95% CI 0·21-0·41; p<0·0001) compared with least fit (≤5 METs) patients (HR 1; n=1060). For those not treated with statins, the HR for least fit participants (n=1024) was 1·35 (95% CI 1·17-1·54; p<0·0001) and progressively decreased to 0·53 (95% CI 0·44-0·65; p<0·0001) for those in the highest fitness category (n=1498).
Interpretation: Statin treatment and increased fitness are independently associated with low mortality among dyslipidaemic individuals. The combination of statin treatment and increased fitness resulted in substantially lower mortality risk than either alone, reinforcing the importance of physical activity for individuals with dyslipidaemia.
Funding: None.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Comment in
-
Prescription of physical activity: an undervalued intervention.Lancet. 2013 Feb 2;381(9864):356-7. doi: 10.1016/S0140-6736(12)61804-2. Epub 2012 Nov 28. Lancet. 2013. PMID: 23199848 No abstract available.
-
Dyslipidaemia: Exercise reduces mortality in patients receiving statins.Nat Rev Endocrinol. 2013 Feb;9(2):66. doi: 10.1038/nrendo.2012.241. Epub 2012 Dec 18. Nat Rev Endocrinol. 2013. PMID: 23296161 No abstract available.
-
Statin and exercise prescription.Lancet. 2013 May 11;381(9878):1621. doi: 10.1016/S0140-6736(13)61015-6. Lancet. 2013. PMID: 23663941 No abstract available.
-
Statin and exercise prescription.Lancet. 2013 May 11;381(9878):1622. doi: 10.1016/S0140-6736(13)61016-8. Lancet. 2013. PMID: 23663942 No abstract available.
-
Statin and exercise prescription - Authors' reply.Lancet. 2013 May 11;381(9878):1622-3. doi: 10.1016/S0140-6736(13)61018-1. Lancet. 2013. PMID: 23663943 No abstract available.
-
Statin and exercise prescription.Lancet. 2013 May 11;381(9878):1622. doi: 10.1016/S0140-6736(13)61017-X. Lancet. 2013. PMID: 23663944 No abstract available.
Similar articles
-
Statins modulate the mortality risk associated with obesity and cardiorespiratory fitness in diabetics.J Clin Endocrinol Metab. 2013 Aug;98(8):3394-401. doi: 10.1210/jc.2013-1431. Epub 2013 Jun 19. J Clin Endocrinol Metab. 2013. PMID: 23783095
-
Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans.Am J Hypertens. 2014 Mar;27(3):422-30. doi: 10.1093/ajh/hpt241. Epub 2014 Jan 16. Am J Hypertens. 2014. PMID: 24436326
-
Cardiorespiratory Fitness and Incidence of Type 2 Diabetes in United States Veterans on Statin Therapy.Am J Med. 2017 Oct;130(10):1192-1198. doi: 10.1016/j.amjmed.2017.04.042. Epub 2017 May 25. Am J Med. 2017. PMID: 28552431
-
Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: A systematic review and meta-analysis.Eur J Prev Cardiol. 2017 Jun;24(9):907-916. doi: 10.1177/2047487317691874. Epub 2017 Feb 13. Eur J Prev Cardiol. 2017. PMID: 28436720 Review.
-
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2016 Nov 15;316(19):2008-2024. doi: 10.1001/jama.2015.15629. JAMA. 2016. PMID: 27838722 Review.
Cited by
-
Cardiovascular Disease in Chronic Kidney Disease: Implications of Cardiorespiratory Fitness, Race, and Sex.Rev Cardiovasc Med. 2024 Oct 11;25(10):365. doi: 10.31083/j.rcm2510365. eCollection 2024 Oct. Rev Cardiovasc Med. 2024. PMID: 39484137 Free PMC article. Review.
-
Association of statins with peak oxygen consumption in 4,941 adults: A cross-sectional study.Int J Cardiol Heart Vasc. 2024 Jul 20;53:101471. doi: 10.1016/j.ijcha.2024.101471. eCollection 2024 Aug. Int J Cardiol Heart Vasc. 2024. PMID: 39149614 Free PMC article.
-
Racial and Gender Differences in Cardiorespiratory Fitness and Atrial Fibrillation.Rev Cardiovasc Med. 2024 Jul 11;25(7):261. doi: 10.31083/j.rcm2507261. eCollection 2024 Jul. Rev Cardiovasc Med. 2024. PMID: 39139428 Free PMC article. Review.
-
Cardiorespiratory Fitness and Health Outcomes Across the Spectra of Age, Gender, and Race.Rev Cardiovasc Med. 2024 Jan 10;25(1):15. doi: 10.31083/j.rcm2501015. eCollection 2024 Jan. Rev Cardiovasc Med. 2024. PMID: 39077644 Free PMC article. No abstract available.
-
Physical Fitness and Cardiometabolic Disease.Rev Cardiovasc Med. 2022 Jul 20;23(8):259. doi: 10.31083/j.rcm2308259. eCollection 2022 Aug. Rev Cardiovasc Med. 2022. PMID: 39076645 Free PMC article. No abstract available.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
